The Saudi Food and Drug Authority (SFDA) PRESS RELEASE- Use of Gilenya® and Cardiovascular Adverse Events after the First dose.

By: Fawaz Alharbi, B. Pharm, MSc, CPP & Ali Y. Alshahrani, B. Pharm

The Saudi Food and Drug Authority (SFDA) would like to inform health care professionals that SFDA has evaluated the recent safety issue concerning the risk of death and cardiovascular events reported after the first dose of multiple sclerosis drug Gilenya® (fingolimod).

The Saudi Food and Drug Authority (SFDA) would like to inform health care professionals that SFDA has evaluated the recent safety issue concerning the risk of death and cardiovascular events reported after the first dose of multiple sclerosis drug Gilenya® (fingolimod).

Gilenya® is an oral medication for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

The evaluation was included a reported case of patient with multiple sclerosis who died within 24 hours after receiving the first dose of Gilenya® clinical studies and several cases of bradycardia and atrioventricular block that have been reported after the 1st dose of Gilenya®.

As a result, there was an increase in the cardiovascular events reporting rate in patients who receive the 1st dose of Gilenya®. In addition, two clinical studies showed an increase in the incidence of bradycardia after the 1st dose of Gilenya® administration and in both studies the incidence of bradycardia was higher for patients receiving higher doses of Gilenya®.

Considerations that should be taken by health care professionals:

1. The use of Gilenya® should be contraindicated in patients with:
   a. Recent (within the last 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure.
   b. History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker
   c. Baseline QTc interval ≥500 ms
   d. Treatment with Class Ia or Class III anti-arrhythmic drugs

2. First dose monitoring should include the followings:
   a. Observe all patients for signs and symptoms of bradycardia for at least after first dose with hourly pulse and blood pressure measurement. Obtain Electrocardiogram (ECG) prior to dosing and at the end of the observation period
   b. Patients who develop a heart rate <45 bpm, or a new onset 2nd degree or higher atrioventricular block should be monitored until resolution of the finding. Patients at lowest post-dose heart rate at the end of the observation period should be monitored until heart rate increases.
   c. In patients experiencing symptomatic bradycardia, begin continuous ECG monitoring until the symptoms have resolved; if pharmacological intervention is required to treat bradycardia, continuous ECG monitoring should continue overnight in a medical facility, and first-dose monitoring procedures should be repeated for the second dose.
   d. Patients at higher risk of symptomatic bradycardia or heart block because of a coexisting medical condition or certain concomitant medications should be observed overnight with continuous ECG monitoring.
**Saudi Food and Drug Authority (SFDA)**

**PRESS RELEASE- Use of Dasatinib (Sprycel®) and risk of Pulmonary arterial hypertension (PAH).**

By: Ali Y. Alshahrani, B. Pharm

The Saudi Food and Drug Authority (SFDA) would like to provide all health care professionals with important safety information about the potential increase in the risk of pulmonary arterial hypertension (PAH) with use of dasatinib (Sprycel®).

Sprycel® is an oral medication approved in Saudi Arabia for the treatment of adults who newly diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML whom no longer benefit from or did not tolerate other treatments including imatinib and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) whom no longer benefit from or did not tolerate other treatments.

The evaluation was included published observational study and safety signals detection of WHO adverse drug reaction database [Vigibase®].

An observational study aimed to investigate the risk factors and management and outcome of pleural effusion associated with dasatinib therapy was evaluated. This study included 138 patients, the median time receiving dasatinib therapy was 42 weeks, pleural effusion occurred in 48 patients. In 18 patients with pleural effusion a statistical significant increase in the right ventricular systolic pressure (RVSP) was observed at the onset of pleural effusion when compared to the baseline (P=0.0014). RVSP is considered a noninvasive surrogate marker of pulmonary artery pressure.

Vigibase® data mining was performed and 46 case reports of pulmonary hypertension (PH) with use of dasatinib were retrieved. Of these 46 cases, 30 cases were reported as pulmonary hypertension and 16 cases as pulmonary arterial hypertension (PAH).

After reviewing data from observational study and safety signals detection of Vigibase® with respect to the risk of pulmonary arterial hypertension in patients using dasatinib, we concluded that the use of dasatinib have an association with an increased risk of PAH which need some considerations to be taken by healthcare professionals before dasatinib therapy initiation.

**Considerations that should be taken by health care professionals:**

1. Patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease before starting dasatinib.
2. An echocardiography should be performed at treatment initiation in every patient presenting symptoms of cardiac disease and considered in patients with risk factors for cardiac or pulmonary disease.
3. Patients who develop dyspnea and fatigue after initiation of dasatinib should be evaluated for common etiologies (e.g. pleural effusion, pulmonary edema, anemia, lung infiltration).
4. During the evaluation process, guidelines for non-hematologic adverse reactions should be followed. If the adverse reaction is severe, treatment must be withheld until the event has resolved or improved.
5. If no alternative diagnosis is found, a diagnosis of PAH should be considered. The diagnostic approach for PAH should follow standard practice guidelines.
6. If PAH is confirmed, dasatinib should be permanently discontinued. Follow-up of patients diagnosed with PAH should follow standard practice guidelines.

---

**Use of Fluconazole during pregnancy and the Risk of birth defects.**

By: Naser A. Aljaser, B. pharm, MSc

Although there is no strong evidence of the association between birth defects and using fluconazole during pregnancy, many cases were reported in the medical literature. Fluconazole is used to treat serious fungal infections, including yeast infections of the vagina, mouth, throat, esophagus and other organs. Furthermore, it is used to treat specific diseases such as meningitis. using fluconazole during pregnancy is occasionally prescriptions as a treatment for vaginal fungal infection. In addition, the US Food and Drug Administration FDA has released a safety communication regarding the risk of using fluconazole during pregnancy. It has been found that fluconazole might be associated with higher risk of birth defect to the fetus.

Literately, birth defects are not associated with lower doses of fluconazole. A cohort study was conducted by Nørgaard et al to investigate the association of using Fluconazole during pregnancy and the risk of congenital malformation. The study recruited 1079 participants, and found that there was no significant risk of congenital malformation associated with using fluconazole.1 Vaginal fungal infections are usually treated with small doses of fluconazole; however, in some cases higher doses may...
Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) use during pregnancy.

By: Mubarak S. Alshahrani, B. Pharm, MSc

Despite warnings related to the use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) during pregnancy, a number of case report series and recent meta-analysis have highlighted the issue of using them in childbearing mothers. In addition, the European Medicines Agency (EMA) has considered ACEIs and ARBs use during second and third trimesters of pregnancy as a contraindication.1,2 Furthermore, the issue of prescribing ACEIs and ARBs to childbearing women, though small but apparently present, raises issues of awareness among medical practitioners in relation to the related harmful consequences of such prescribing.

In a recent meta-analysis published in 2012, a total of 186 well-documented cases of prenatal exposure to ACEIs and ARBs were registered in childbearing mothers. The adverse events, which were 118 well-documented cases reported in the ACEI class, ranged from death or renal failure to pulmonary distress syndrome (figure-1) 3. Also, ARB-related adverse events during pregnancy (e.g. oligohydramnios to limb defects in born children), were well-documented in 68 cases (figure-1). Moreover, the rennin-angiotensin system (RAS) is an important factor in the development of the prenatal renal system and blockade of such system with either ARBs or ACEIs may result in a number of serious adverse events.3 Therefore, the Saudi Food and Drug Authority is, indeed, updating the patient’s information leaflets (PIL) for a number of ARB medications in the Saudi market with regard to the changes related to the use of these medications in each trimester of pregnancy.

References:
Guidance for the Registration Requirements for Energy Drinks.

By: Khalid E. Alanazi, BSc., MSc.

Energy drinks are those with high caffeine levels which are claimed by manufacturers to give the consumer more ‘energy’ than a typical soft drink. The Saudi Food and Drug Authority (SFDA) has published a guidance for energy drinks registration. Energy drinks are defined as “carbonated or non-carbonated drinks prepared essentially from water, natural carbohydrates, caffeine and other elements such as vitamins, minerals, amino acids and other permitted additive materials. Juices, fruit pulp and plant extract can be added”. Energy drinks registration file can be submitted to SFDA by applicants in both hard-copy and soft-copy versions to get marketing approval in Saudi Arabia.

Requirements for labeling information of Energy Drinks:

The following information should appear prominently on product labeling (in Arabic and English) and company websites in which the product is featured:

- Drinking more than two bottles per day may be harmful to your health.
- Energy drinks should not be consumed by pregnant and breastfeeding women.
- Energy drinks should not be consumed by heart hypertensive or diabetic patients.
- Energy drinks should not be consumed by children under 16 years old.
- Energy drinks should not be consumed by athletes during sport activities.
- Not suitable for persons sensitive to caffeine.
- Medical claims and any phrases (e.g., energy drink, power drink, etc) that may support energy drinks consumed are prohibited.
- Maximum daily allowance of energy drinks.

General considerations:

- Producing and importing energy drinks to Saudi Arabia is prohibited, unless approved by SFDA.
- Energy drinks may contain other ingredients, such as glucuronolactone and taurine, and sometimes vitamins, minerals and herbal substances. Such ingredients should be in compliance with the requirements of handling energy drinks (GSO 1926/2009):
  - Not more than 32 mg of Caffeine, 20 mg of Inositol, 240 mg of Glucuronolactone and 400 mg of Taurine for each 100 ml of energy drinks.
  - Not more than 0.1 ppm of arsenic, 0.2 ppm of Lead, 2.0 ppm of Copper, 2.0 ppm of Zinc, 0.5 ppm of Iron and 250 ppm of Tin for each energy drink.
- Energy drinks should be presented with detailed information about their contents.
- Energy drink should be free from doping drugs and other hormones.

References:

One concern is that both TCS and TCC have almost similar mechanism of action (MOA). Thus, long term use of antibacterial soaps may lead into an increase in bacterial resistance. The other concern is because of TCS can be contaminated by dioxin compounds either due to the ability of TCS to convert to dioxins in the presence of free chlorine, in tap water and UV light or production of dioxins during TCS syntheses. Dioxins, especially as 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) are considered carcinogenic substances and hormonal disruptors.

Various regulatory authorities worldwide have released information regarding the use of antibacterial soaps. The US Food and Drug Administration FDA has announced that the use of TCS in soaps and body washes has no additional benefits to health over the use of regular soaps.

In addition, the ministry of environment in Germany in 2002 advised consumers against using cleaning agents containing antibacterial ingredients and manufacturers to stop marketing and advertising their antibacterial soaps. Moreover, in 2012 health Canada recalled contaminated foaming hand soaps (0.3% TCS) with (Pseudomonas aeruginosa).

**General**

**Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism.**

*By: Mohammed A. Barasain, RPh*

*The following is a summary of an article published in the New England Journal of Medicine (NEJM) issue of November 22nd of 2012.*

**Background:**

Patients who have had a first episode of unprovoked venous thromboembolism have a high risk of recurrence after anticoagulants are discontinued. Aspirin may be effective in preventing a recurrence of venous thromboembolism.

**Methods:**

Researchers randomly assigned 822 patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism to receive aspirin, at a dose of 100 mg daily, or placebo for up to 4 years. The primary outcome was a recurrence of venous thromboembolism.

**Results:**

During a median follow-up period of 37.2 months, venous thromboembolism recurred in 73 of 411 patients assigned to placebo and in 57 of 411 assigned to aspirin (a rate of 6.5% per year vs. 4.8% per year; hazard ratio with aspirin, 0.74; 95% confidence interval [CI], 0.52 to 1.05; P=0.09). Aspirin reduced the rate of the two pre-specified secondary composite outcomes: the rate of venous thromboembolism, myocardial infarction, stroke, or cardiovascular death was reduced by 34% (a rate of 8.0% per year with placebo vs. 5.2% per year with aspirin; hazard ratio with aspirin, 0.66; 95% CI, 0.48 to 0.92; P=0.01), and the rate of venous thromboembolism, myocardial infarction, stroke, major bleeding, or death from any cause was reduced by 33% (hazard ratio, 0.67; 95% CI, 0.49 to 0.91; P=0.01). There was no significant between-group difference in the rates of major or clinically relevant non-major bleeding episodes (rate of 0.6% per year with placebo vs. 1.1% per year with aspirin, P=0.22) or serious adverse events.

**Conclusion:**

In this study, aspirin, as compared with placebo, did not significantly reduce the rate of recurrence of venous thromboembolism but resulted in a significant reduction in the rate of major vascular events, with improved net clinical benefit. These results substantiate earlier evidence of a therapeutic benefit of aspirin when it is given to patients after initial anticoagulant therapy for a first episode of unprovoked venous thromboembolism.

**References:**

5. A. Aiello. 2003 *Consumer Antibacterial Soaps: Effective or Just Risky?*. Clinical Infectious Disease. 43: 137-147.
**Multivitamins in the Prevention of Cancer in Men (The Physicians’ Health Study II) Randomized Controlled Trial.**

*By: Mohammed A. Barasain, RPh*

The following is a summary of an article published in the *Journal of American Medical Association* (JAMA) issue of November 14th of 2012.

**Background:**
Multivitamin preparations are the most common dietary supplement, taken by at least one-third of all US adults. Observational studies have not provided evidence regarding associations of multivitamin use with total and site-specific cancer incidence or mortality.

**Objectives and Design:**
The objective of this trial was to determine whether long-term multivitamin supplementation decreases the risk of total and site-specific cancer events among men. The trial was a large-scale, randomized, double-blind, placebo-controlled trial (Physicians’ Health Study II) of 14,641 male US physicians initially aged 50 years or older (mean [SD] age, 64.3 [9.2] years), including 1312 men with a history of cancer at randomization, enrolled in a common multivitamin study that began in 1997 with treatment and follow-up through June 1, 2011.

**Intervention:**
Daily multivitamin or placebo.

**Main Outcome Measures:**
- Total cancer (excluding non-melanoma skin cancer), with prostate, colorectal, and other site-specific cancers among the secondary end points.

**Results:**
During a median (interquartile range) follow-up of 11.2 (10.7-13.3) years, there were 2669 men with confirmed cancer, including 1373 cases of prostate cancer and 210 cases of colorectal cancer. Compared with placebo, men taking a daily multivitamin had a statistically significant reduction in the incidence of total cancer (multivitamin and placebo groups, 17.0 and 18.3 events, respectively, per 1000 person-years; hazard ratio [HR], 0.92; 95% CI, 0.86-0.998; P = .04). There was no significant effect of a daily multivitamin on prostate cancer (multivitamin and placebo groups, 9.1 and 9.2 events, respectively, per 1000 person-years; HR, 0.98; 95% CI, 0.88-1.09; P = .76), colorectal cancer (multivitamin and placebo groups, 1.2 and 1.4 events, respectively, per 1000 person-years; HR, 0.89; 95% CI, 0.68-1.17; P = .39), or other site-specific cancers. There was no significant difference in the risk of cancer mortality (multivitamin and placebo groups, 4.9 and 5.6 events, respectively, per 1000 person-years; HR, 0.88; 95% CI, 0.77-1.01; P = .07). Daily multivitamin use was associated with a reduction in total cancer among 1312 men with a baseline history of cancer, enrolled in a common multivitamin study that began in 1997, with treatment and follow-up through June 1, 2011.

**Conclusion:**
In this large prevention trial of male physicians, daily multivitamin supplementation modestly but significantly reduced the risk of total cancer.

**References:**

---

**Editorial Board:**

**General Supervisor:** Prof. Saleh A. Bawazir

**Editor:** Abdullrahman S. Alsultan, B.Pharm, MSc.

**Assistant Editor:** Nawaf M. Alshobaili, B.Pharm, MPH.

**National Drug and Poison Information Center (NDPIC):**
- Fahad A. Al Otaibi, BSc.Pharm, MSc. Clin Pharm.
- Mohammed A. Barasain, RPh.

**National Pharmacovigilance and Drug Safety Center**
- Thamir M Alshammari, PhD, M.S, RPh.
- Fawaz F Alharbi, B.Pharm, MSc.
<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Strength</th>
<th>Price SR</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETYLICYSTEINE</td>
<td>FLUIMUCIL GRANULES FOR ORAL SOLUTION</td>
<td>100MG/1GM</td>
<td>4.65</td>
<td>ZAMBON SWITZERLAND LTD</td>
</tr>
<tr>
<td>ACETYLICYSTEINE</td>
<td>FLUIMUCIL GRANULES FOR ORAL SOLUTION</td>
<td>200MG/1GM</td>
<td>9.35</td>
<td>ZAMBON SWITZERLAND LTD</td>
</tr>
<tr>
<td>AMOXICILLIN, CLAVULANIC ACID</td>
<td>AMOXIPLUS POWDER FOR INJECTION</td>
<td>1.2GM</td>
<td>299.7</td>
<td>ANTIBIOTIC S.E</td>
</tr>
<tr>
<td>AMPICILLIN SODIUM</td>
<td>AMPICILLIN POWDER FOR IV AND IM INJECTION</td>
<td>1GM</td>
<td>198.85</td>
<td>ANTIBIOTIC S.E</td>
</tr>
<tr>
<td>AMPICILLIN SODIUM</td>
<td>AMPICILLIN POWDER FOR IV AND IM INJECTION</td>
<td>500MG</td>
<td>147.4</td>
<td>ANTIBIOTIC S.E</td>
</tr>
<tr>
<td>AMPICILLIN, SALBACTAM</td>
<td>AMPIPLUS POWDER FOR INJECTION</td>
<td>1.5GM</td>
<td>752.5</td>
<td>ANTIBIOTIC S.E</td>
</tr>
<tr>
<td>AZITHROMYCIN</td>
<td>ZITHROMAX POWDER FOR IV INFUSION</td>
<td>500 MG</td>
<td>60.25</td>
<td>AMGEN TECHNOLOGY</td>
</tr>
<tr>
<td>BISOPROLOL FUMARATE</td>
<td>CARDIOPROL TABLETS</td>
<td>10MG</td>
<td>23.05</td>
<td>The Jordanian Pharmaceutical Manufacturing Medical Equipment Co., Ltd. (JPM)</td>
</tr>
<tr>
<td>BISOPROLOL FUMARATE</td>
<td>CARDIOPROL TABLETS</td>
<td>5MG</td>
<td>16.25</td>
<td>The Jordanian Pharmaceutical Manufacturing Medical Equipment Co., Ltd. (JPM)</td>
</tr>
<tr>
<td>BRIMONIDINE TARTRATE</td>
<td>BRIMO-P OPHTHALMIC SOLUTION</td>
<td>0.10%</td>
<td>20.65</td>
<td>JAMUOM PHARMACEUTICALS COMPANY</td>
</tr>
<tr>
<td>BUDESONIDE</td>
<td>ENEMACORT TABLET FOR ENEMA</td>
<td>0.02MG/ML</td>
<td>20.95</td>
<td>MEDICAL UNION PHARMACEUTICALS CO</td>
</tr>
<tr>
<td>ESCITALOPRAM OXALATE</td>
<td>ZELAX FILM COATED CAPLET</td>
<td>10MG</td>
<td>79.3</td>
<td>Jordan Sweden Medical and Sterilization Co.</td>
</tr>
<tr>
<td>ESCITALOPRAM OXALATE</td>
<td>ZELAX FILM COATED CAPLET</td>
<td>20MG</td>
<td>117.1</td>
<td>Jordan Sweden Medical and Sterilization Co.</td>
</tr>
<tr>
<td>MEMANTINE HYDROCHLORIDE</td>
<td>EBIXA FILM COATED TABLETS</td>
<td>20MG</td>
<td>315.45</td>
<td>H. LUNDBECK</td>
</tr>
<tr>
<td>MONTELUKAST SODIUM</td>
<td>AIRFAST FILM COATED TABLETS</td>
<td>10MG</td>
<td>105.7</td>
<td>TABUK PHARMACEUTICAL MANUFACTURING CO.</td>
</tr>
<tr>
<td>MYCOPHENOLATE MOFETIL</td>
<td>MOFETAB FILM COATED TABLET</td>
<td>500 MG</td>
<td>1296.15</td>
<td>TABUK PHARMACEUTICAL MANUFACTURING CO.</td>
</tr>
<tr>
<td>PAROXETINE HYDROCHLORIDE</td>
<td>SEROXAT CR TABLETS</td>
<td>12.5MG</td>
<td>72.8</td>
<td>GLAXOSMITHKLINE (GSK)</td>
</tr>
<tr>
<td>PAROXETINE HYDROCHLORIDE</td>
<td>SEROXAT CR TABLETS</td>
<td>25MG</td>
<td>96.85</td>
<td>GLAXOSMITHKLINE (GSK)</td>
</tr>
<tr>
<td>PYRAZINAMIDE</td>
<td>PYRAZINAMIDE ANTIBIOTICE</td>
<td>500MG</td>
<td>59.85</td>
<td>ANTIBIOTIC S.E</td>
</tr>
<tr>
<td>RAMIPRIL</td>
<td>RAMIPRIL SANDOZ FILM COATED TABLETS</td>
<td>10MG</td>
<td>45.5</td>
<td>HEXAL</td>
</tr>
<tr>
<td>RAMIPRIL</td>
<td>RAMIPRIL SANDOZ FILM COATED TABLETS</td>
<td>2.5MG</td>
<td>25.5</td>
<td>HEXAL</td>
</tr>
<tr>
<td>RAMIPRIL</td>
<td>RAMIPRIL SANDOZ FILM COATED TABLETS</td>
<td>5MG</td>
<td>35.5</td>
<td>HEXAL</td>
</tr>
<tr>
<td>RISPERIDONE</td>
<td>SAXID TABLET</td>
<td>2MG</td>
<td>57.8</td>
<td>The Jordanian Pharmaceutical Manufacturing Medical Equipment Co., Ltd. (JPM)</td>
</tr>
<tr>
<td>RISPERIDONE</td>
<td>SAXID TABLET</td>
<td>4MG</td>
<td>94.8</td>
<td>The Jordanian Pharmaceutical Manufacturing Medical Equipment Co., Ltd. (JPM)</td>
</tr>
<tr>
<td>RIVAROXABAN</td>
<td>XARELTO FILM COATED TABLET</td>
<td>10MG</td>
<td>137.5</td>
<td>BAYER SCHERING PHARMAAG</td>
</tr>
<tr>
<td>SAXAGLIPTIN</td>
<td>ONGLYZA TABLET</td>
<td>5 MG</td>
<td>140.35</td>
<td>BRISTOL-MYERS SQUIBB</td>
</tr>
<tr>
<td>SECnidazole</td>
<td>SECNEZOLE TABLETS</td>
<td>500MG</td>
<td>11.7</td>
<td>The Jordanian Pharmaceutical Manufacturing Medical Equipment Co., Ltd. (JPM)</td>
</tr>
<tr>
<td>TERBINAFINE HCL</td>
<td>TERBIN CREAM</td>
<td>1%</td>
<td>5.4</td>
<td>GLOBAL NABI</td>
</tr>
<tr>
<td>TIZANIDINE</td>
<td>TILAX TABLET</td>
<td>2 MG</td>
<td>16.4</td>
<td>RIYADH PHARMA</td>
</tr>
<tr>
<td>TIZANIDINE</td>
<td>TILAX TABLET</td>
<td>4 MG</td>
<td>26.9</td>
<td>RIYADH PHARMA</td>
</tr>
</tbody>
</table>
المخصوص العربي:

الجرعة الأولى من استخدام مستحضر (Gilenya®):

大专ية الوعى لدواء القدم ودجاجة فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).

1. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
2. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
3. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
4. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).

المخصص العربي

تحذير حول خطط حدوث ارتفاع الضغط الشرياني

الرويد عند استخدام مستحضر داساتينيب (Sprycel®).

ف Dame التهابي العضلات الشرياني والرويد، دون تفاعلات تشكل إصابات محتملة للعظام ذات جرسيًا وبدور ارتفاع الضغط الشرياني عند استخدام المستحضر

1. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
2. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
3. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
4. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).

المخصص العربي

تحذير حول خطط حدوث ارتفاع الضغط الشرياني

الرويد عند استخدام مستحضر داساتينيب (Sprycel®).

Fame التهابي العضلات الشرياني والرويد، دون تفاعلات تشكل إصابات محتملة للعظام ذات جرسيًا وبدور ارتفاع الضغط الشرياني عند استخدام المستحضر

1. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
2. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
3. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
4. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).

المخصص العربي

تحذير حول خطط حدوث ارتفاع الضغط الشرياني

الرويد عند استخدام مستحضر داساتينيب (Sprycel®).

Fame التهابي العضلات الشرياني والرويد، دون تفاعلات تشكل إصابات محتملة للعظام ذات جرسيًا وبدور ارتفاع الضغط الشرياني عند استخدام المستحضر

1. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
2. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
3. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
4. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).

المخصص العربي

تحذير حول خطط حدوث ارتفاع الضغط الشرياني

الرويد عند استخدام مستحضر داساتينيب (Sprycel®).

Fame التهابي العضلات الشرياني والرويد، دون تفاعلات تشكل إصابات محتملة للعظام ذات جرسيًا وبدور ارتفاع الضغط الشرياني عند استخدام المستحضر

1. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
2. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
3. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
4. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).

المخصص العربي

تحذير حول خطط حدوث ارتفاع الضغط الشرياني

الرويد عند استخدام مستحضر داساتينيب (Sprycel®).

Fame التهابي العضلات الشرياني والرويد، دون تفاعلات تشكل إصابات محتملة للعظام ذات جرسيًا وبدور ارتفاع الضغط الشرياني عند استخدام المستحضر

1. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
2. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
3. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).
4. متاحية استخدام دواء القدم ومثال فصول الطيور المريض، ليلة، 3 ساعات بعد التناول (Gilenya®).